Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation

Chiara Degirolamo, Salvatore Modica, Michele Vacca, Giuseppe Di Tullio, Annalisa Morgano, Andria D'Orazio, Kristina Kannisto, Paolo Parini, Antonio Moschetta

Research output: Contribution to journalArticle

Abstract

Farnesoid X receptor (FXR) is the master regulator of bile acid (BA) homeostasis because it controls BA synthesis, influx, efflux, and detoxification in the gut/liver axis. Deregulation of BA homeostasis has been linked to hepatocellular carcinoma (HCC), and spontaneous hepatocarcinogenesis has been observed in FXR-null mice. This dreaded liver neoplasm has been associated with both FXR gene deletion and BA-mediated metabolic abnormalities after inactivation of FXR transcriptional activity. In the present study, we addressed the hypothesis that intestinal selective FXR reactivation would be sufficient to restore the fibroblast growth factor 15 (FGF15)/cholesterol-7alpha-hydroxylase (Cyp7a1) enterohepatic axis and eventually provide protection against HCC. To this end, we generated FXR-null mice with re-expression of constitutively active FXR in enterocytes (FXR-/-iVP16FXR) and corresponding control mice (FXR-/-iVP16). In FXR-null mice, intestinal selective FXR reactivation normalized BA enterohepatic circulation along with up-regulation of intestinal FXR transcriptome and reduction of hepatic BA synthesis. At 16 months of age, intestinal FXR reactivation protected FXR-null mice from spontaneous HCC development that occurred in otherwise FXR-null mice. Activation of intestinal FXR conferred hepatoprotection by restoring hepatic homeostasis, limiting cellular proliferation through reduced cyclinD1 expression, decreasing hepatic inflammation and fibrosis (decreased signal transducer and activator of transcription 3 activation and curtailed collagen deposition). Conclusion: Intestinal FXR is sufficient to restore BA homeostasis through the FGF15 axis and prevent progression of liver damage to HCC even in the absence of hepatic FXR. Intestinal-selective FXR modulators could stand as potential therapeutic intervention to prevent this devastating hepatic malignancy, even if carrying a somatic FXR mutation.

Original languageEnglish
Pages (from-to)161-170
Number of pages10
JournalHepatology
Volume61
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Bile Acids and Salts
Liver
Hepatocellular Carcinoma
Homeostasis
Fibroblast Growth Factors
Cholesterol 7-alpha-Hydroxylase
Enterohepatic Circulation
X Chromosome Inactivation
STAT3 Transcription Factor
Enterocytes
Gene Deletion
Liver Neoplasms
Transcriptome
Transcriptional Activation
Fibrosis
Up-Regulation
Collagen
Cell Proliferation
Inflammation
Mutation

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., ... Moschetta, A. (2015). Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology, 61(1), 161-170. https://doi.org/10.1002/hep.27274

Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. / Degirolamo, Chiara; Modica, Salvatore; Vacca, Michele; Di Tullio, Giuseppe; Morgano, Annalisa; D'Orazio, Andria; Kannisto, Kristina; Parini, Paolo; Moschetta, Antonio.

In: Hepatology, Vol. 61, No. 1, 01.01.2015, p. 161-170.

Research output: Contribution to journalArticle

Degirolamo, C, Modica, S, Vacca, M, Di Tullio, G, Morgano, A, D'Orazio, A, Kannisto, K, Parini, P & Moschetta, A 2015, 'Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation', Hepatology, vol. 61, no. 1, pp. 161-170. https://doi.org/10.1002/hep.27274
Degirolamo, Chiara ; Modica, Salvatore ; Vacca, Michele ; Di Tullio, Giuseppe ; Morgano, Annalisa ; D'Orazio, Andria ; Kannisto, Kristina ; Parini, Paolo ; Moschetta, Antonio. / Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. In: Hepatology. 2015 ; Vol. 61, No. 1. pp. 161-170.
@article{9b3f460e2bb64b6e89c47e0d517d0e70,
title = "Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation",
abstract = "Farnesoid X receptor (FXR) is the master regulator of bile acid (BA) homeostasis because it controls BA synthesis, influx, efflux, and detoxification in the gut/liver axis. Deregulation of BA homeostasis has been linked to hepatocellular carcinoma (HCC), and spontaneous hepatocarcinogenesis has been observed in FXR-null mice. This dreaded liver neoplasm has been associated with both FXR gene deletion and BA-mediated metabolic abnormalities after inactivation of FXR transcriptional activity. In the present study, we addressed the hypothesis that intestinal selective FXR reactivation would be sufficient to restore the fibroblast growth factor 15 (FGF15)/cholesterol-7alpha-hydroxylase (Cyp7a1) enterohepatic axis and eventually provide protection against HCC. To this end, we generated FXR-null mice with re-expression of constitutively active FXR in enterocytes (FXR-/-iVP16FXR) and corresponding control mice (FXR-/-iVP16). In FXR-null mice, intestinal selective FXR reactivation normalized BA enterohepatic circulation along with up-regulation of intestinal FXR transcriptome and reduction of hepatic BA synthesis. At 16 months of age, intestinal FXR reactivation protected FXR-null mice from spontaneous HCC development that occurred in otherwise FXR-null mice. Activation of intestinal FXR conferred hepatoprotection by restoring hepatic homeostasis, limiting cellular proliferation through reduced cyclinD1 expression, decreasing hepatic inflammation and fibrosis (decreased signal transducer and activator of transcription 3 activation and curtailed collagen deposition). Conclusion: Intestinal FXR is sufficient to restore BA homeostasis through the FGF15 axis and prevent progression of liver damage to HCC even in the absence of hepatic FXR. Intestinal-selective FXR modulators could stand as potential therapeutic intervention to prevent this devastating hepatic malignancy, even if carrying a somatic FXR mutation.",
author = "Chiara Degirolamo and Salvatore Modica and Michele Vacca and {Di Tullio}, Giuseppe and Annalisa Morgano and Andria D'Orazio and Kristina Kannisto and Paolo Parini and Antonio Moschetta",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/hep.27274",
language = "English",
volume = "61",
pages = "161--170",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation

AU - Degirolamo, Chiara

AU - Modica, Salvatore

AU - Vacca, Michele

AU - Di Tullio, Giuseppe

AU - Morgano, Annalisa

AU - D'Orazio, Andria

AU - Kannisto, Kristina

AU - Parini, Paolo

AU - Moschetta, Antonio

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Farnesoid X receptor (FXR) is the master regulator of bile acid (BA) homeostasis because it controls BA synthesis, influx, efflux, and detoxification in the gut/liver axis. Deregulation of BA homeostasis has been linked to hepatocellular carcinoma (HCC), and spontaneous hepatocarcinogenesis has been observed in FXR-null mice. This dreaded liver neoplasm has been associated with both FXR gene deletion and BA-mediated metabolic abnormalities after inactivation of FXR transcriptional activity. In the present study, we addressed the hypothesis that intestinal selective FXR reactivation would be sufficient to restore the fibroblast growth factor 15 (FGF15)/cholesterol-7alpha-hydroxylase (Cyp7a1) enterohepatic axis and eventually provide protection against HCC. To this end, we generated FXR-null mice with re-expression of constitutively active FXR in enterocytes (FXR-/-iVP16FXR) and corresponding control mice (FXR-/-iVP16). In FXR-null mice, intestinal selective FXR reactivation normalized BA enterohepatic circulation along with up-regulation of intestinal FXR transcriptome and reduction of hepatic BA synthesis. At 16 months of age, intestinal FXR reactivation protected FXR-null mice from spontaneous HCC development that occurred in otherwise FXR-null mice. Activation of intestinal FXR conferred hepatoprotection by restoring hepatic homeostasis, limiting cellular proliferation through reduced cyclinD1 expression, decreasing hepatic inflammation and fibrosis (decreased signal transducer and activator of transcription 3 activation and curtailed collagen deposition). Conclusion: Intestinal FXR is sufficient to restore BA homeostasis through the FGF15 axis and prevent progression of liver damage to HCC even in the absence of hepatic FXR. Intestinal-selective FXR modulators could stand as potential therapeutic intervention to prevent this devastating hepatic malignancy, even if carrying a somatic FXR mutation.

AB - Farnesoid X receptor (FXR) is the master regulator of bile acid (BA) homeostasis because it controls BA synthesis, influx, efflux, and detoxification in the gut/liver axis. Deregulation of BA homeostasis has been linked to hepatocellular carcinoma (HCC), and spontaneous hepatocarcinogenesis has been observed in FXR-null mice. This dreaded liver neoplasm has been associated with both FXR gene deletion and BA-mediated metabolic abnormalities after inactivation of FXR transcriptional activity. In the present study, we addressed the hypothesis that intestinal selective FXR reactivation would be sufficient to restore the fibroblast growth factor 15 (FGF15)/cholesterol-7alpha-hydroxylase (Cyp7a1) enterohepatic axis and eventually provide protection against HCC. To this end, we generated FXR-null mice with re-expression of constitutively active FXR in enterocytes (FXR-/-iVP16FXR) and corresponding control mice (FXR-/-iVP16). In FXR-null mice, intestinal selective FXR reactivation normalized BA enterohepatic circulation along with up-regulation of intestinal FXR transcriptome and reduction of hepatic BA synthesis. At 16 months of age, intestinal FXR reactivation protected FXR-null mice from spontaneous HCC development that occurred in otherwise FXR-null mice. Activation of intestinal FXR conferred hepatoprotection by restoring hepatic homeostasis, limiting cellular proliferation through reduced cyclinD1 expression, decreasing hepatic inflammation and fibrosis (decreased signal transducer and activator of transcription 3 activation and curtailed collagen deposition). Conclusion: Intestinal FXR is sufficient to restore BA homeostasis through the FGF15 axis and prevent progression of liver damage to HCC even in the absence of hepatic FXR. Intestinal-selective FXR modulators could stand as potential therapeutic intervention to prevent this devastating hepatic malignancy, even if carrying a somatic FXR mutation.

UR - http://www.scopus.com/inward/record.url?scp=84920964414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920964414&partnerID=8YFLogxK

U2 - 10.1002/hep.27274

DO - 10.1002/hep.27274

M3 - Article

C2 - 24954587

AN - SCOPUS:84920964414

VL - 61

SP - 161

EP - 170

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -